| molecular function |
|---|
| | GO:0043027 | | cysteine-type endopeptidase inhibitor activity involved in apoptotic process | | Stops, prevents or reduces the activity of a cysteine-type endopeptidase involved in the apoptotic process. |
| | GO:0016874 | | ligase activity | | Catalysis of the joining of two substances, or two groups within a single molecule, with the concomitant hydrolysis of the diphosphate bond in ATP or a similar triphosphate. |
| | GO:0046872 | | metal ion binding | | Interacting selectively and non-covalently with any metal ion. |
| | GO:0047485 | | protein N-terminus binding | | Interacting selectively and non-covalently with a protein N-terminus, the end of any peptide chain at which the 2-amino (or 2-imino) function of a constituent amino acid is not attached in peptide linkage to another amino-acid residue. |
| | GO:0005515 | | protein binding | | Interacting selectively and non-covalently with any protein or protein complex (a complex of two or more proteins that may include other nonprotein molecules). |
| | GO:0003713 | | transcription coactivator activity | | Interacting selectively and non-covalently with a activating transcription factor and also with the basal transcription machinery in order to increase the frequency, rate or extent of transcription. Cofactors generally do not bind the template nucleic acid, but rather mediate protein-protein interactions between activating transcription factors and the basal transcription machinery. |
| | GO:0016740 | | transferase activity | | Catalysis of the transfer of a group, e.g. a methyl group, glycosyl group, acyl group, phosphorus-containing, or other groups, from one compound (generally regarded as the donor) to another compound (generally regarded as the acceptor). Transferase is the systematic name for any enzyme of EC class 2. |
| | GO:0004842 | | ubiquitin-protein transferase activity | | Catalysis of the transfer of ubiquitin from one protein to another via the reaction X-Ub + Y --> Y-Ub + X, where both X-Ub and Y-Ub are covalent linkages. |
| | GO:0008270 | | zinc ion binding | | Interacting selectively and non-covalently with zinc (Zn) ions. |
| biological process |
|---|
| | GO:0007249 | | I-kappaB kinase/NF-kappaB signaling | | The process in which a signal is passed on to downstream components within the cell through the I-kappaB-kinase (IKK)-dependent activation of NF-kappaB. The cascade begins with activation of a trimeric IKK complex (consisting of catalytic kinase subunits IKKalpha and/or IKKbeta, and the regulatory scaffold protein NEMO) and ends with the regulation of transcription of target genes by NF-kappaB. In a resting state, NF-kappaB dimers are bound to I-kappaB proteins, sequestering NF-kappaB in the cytoplasm. Phosphorylation of I-kappaB targets I-kappaB for ubiquitination and proteasomal degradation, thus releasing the NF-kappaB dimers, which can translocate to the nucleus to bind DNA and regulate transcription. |
| | GO:0038061 | | NIK/NF-kappaB signaling | | The process in which a signal is passed on to downstream components within the cell through the NIK-dependent processing and activation of NF-KappaB. Begins with activation of the NF-KappaB-inducing kinase (NIK), which in turn phosphorylates and activates IkappaB kinase alpha (IKKalpha). IKKalpha phosphorylates the NF-Kappa B2 protein (p100) leading to p100 processing and release of an active NF-KappaB (p52). |
| | GO:0035666 | | TRIF-dependent toll-like receptor signaling pathway | | Any series of molecular signals generated as a consequence of binding to a toll-like receptor where the TRIF adaptor mediates transduction of the signal. Toll-like receptors directly bind pattern motifs from a variety of microbial sources to initiate innate immune response. |
| | GO:0006915 | | apoptotic process | | A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died. |
| | GO:0007166 | | cell surface receptor signaling pathway | | A series of molecular signals initiated by activation of a receptor on the surface of a cell. The pathway begins with binding of an extracellular ligand to a cell surface receptor, or for receptors that signal in the absence of a ligand, by ligand-withdrawal or the activity of a constitutively active receptor. The pathway ends with regulation of a downstream cellular process, e.g. transcription. |
| | GO:0006921 | | cellular component disassembly involved in execution phase of apoptosis | | The breakdown of structures such as organelles, proteins, or other macromolecular structures during apoptosis. |
| | GO:1990001 | | inhibition of cysteine-type endopeptidase activity involved in apoptotic process | | Any process that prevents the activation of an inactive cysteine-type endopeptidase involved in an apoptotic process. |
| | GO:0090307 | | mitotic spindle assembly | | The aggregation, arrangement and bonding together of a set of components to form the spindle that contributes to the process of mitosis. |
| | GO:0070266 | | necroptotic process | | A programmed necrotic cell death process which begins when a cell receives a signal (e.g. a ligand binding to a death receptor or to a Toll-like receptor), and proceeds through a series of biochemical events (signaling pathways), characterized by activation of receptor-interacting serine/threonine-protein kinase 1 and/or 3 (RIPK1/3, also called RIP1/3) and by critical dependence on mixed lineage kinase domain-like (MLKL), and which typically lead to common morphological features of necrotic cell death. The process ends when the cell has died. The process is divided into a signaling phase, and an execution phase, which is triggered by the former. |
| | GO:0043066 | | negative regulation of apoptotic process | | Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process. |
| | GO:0060546 | | negative regulation of necroptotic process | | Any process that decreases the rate, frequency or extent of a necroptotic process, a necrotic cell death process that results from the activation of endogenous cellular processes, such as signaling involving death domain receptors or Toll-like receptors. |
| | GO:1902443 | | negative regulation of ripoptosome assembly involved in necroptotic process | | Any process that stops, prevents or reduces the frequency, rate or extent of ripoptosome assembly involved in a necroptotic process. |
| | GO:0001890 | | placenta development | | The process whose specific outcome is the progression of the placenta over time, from its formation to the mature structure. The placenta is an organ of metabolic interchange between fetus and mother, partly of embryonic origin and partly of maternal origin. |
| | GO:0043123 | | positive regulation of I-kappaB kinase/NF-kappaB signaling | | Any process that activates or increases the frequency, rate or extent of I-kappaB kinase/NF-kappaB signaling. |
| | GO:1902524 | | positive regulation of protein K48-linked ubiquitination | | Any process that activates or increases the frequency, rate or extent of protein K48-linked ubiquitination. |
| | GO:1902523 | | positive regulation of protein K63-linked ubiquitination | | Any process that activates or increases the frequency, rate or extent of protein K63-linked ubiquitination. |
| | GO:1902527 | | positive regulation of protein monoubiquitination | | Any process that activates or increases the frequency, rate or extent of protein monoubiquitination. |
| | GO:0043161 | | proteasome-mediated ubiquitin-dependent protein catabolic process | | The chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, and mediated by the proteasome. |
| | GO:0051291 | | protein heterooligomerization | | The process of creating protein oligomers, compounds composed of a small number, usually between three and ten, of component monomers that are not all identical. Oligomers may be formed by the polymerization of a number of monomers or the depolymerization of a large protein polymer. |
| | GO:0000209 | | protein polyubiquitination | | Addition of multiple ubiquitin groups to a protein, forming a ubiquitin chain. |
| | GO:0039535 | | regulation of RIG-I signaling pathway | | Any process that modulates the frequency, rate or extent of the series of molecular signals generated as a consequence of the cytoplasmic pattern recognition receptor (PRR) RIG-1 (also known as DDX58) binding to viral RNA. |
| | GO:0042981 | | regulation of apoptotic process | | Any process that modulates the occurrence or rate of cell death by apoptotic process. |
| | GO:0051726 | | regulation of cell cycle | | Any process that modulates the rate or extent of progression through the cell cycle. |
| | GO:0045595 | | regulation of cell differentiation | | Any process that modulates the frequency, rate or extent of cell differentiation, the process in which relatively unspecialized cells acquire specialized structural and functional features. |
| | GO:0042127 | | regulation of cell proliferation | | Any process that modulates the frequency, rate or extent of cell proliferation. |
| | GO:2000116 | | regulation of cysteine-type endopeptidase activity | | Any process that modulates the frequency, rate or extent of cysteine-type endopeptidase activity. |
| | GO:0050727 | | regulation of inflammatory response | | Any process that modulates the frequency, rate or extent of the inflammatory response, the immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. |
| | GO:0045088 | | regulation of innate immune response | | Any process that modulates the frequency, rate or extent of the innate immune response, the organism's first line of defense against infection. |
| | GO:0060544 | | regulation of necroptotic process | | Any process that modulates the rate, frequency or extent of a necroptotic process, a necrotic cell death process that results from the activation of endogenous cellular processes, such as signaling involving death domain receptors or Toll-like receptors. |
| | GO:0010939 | | regulation of necrotic cell death | | Any process that modulates the rate, frequency or extent of necrotic cell death. Necrotic cell death is a cell death process that is morphologically characterized by a gain in cell volume (oncosis), swelling of organelles, plasma membrane rupture and subsequent loss of intracellular contents. |
| | GO:0070424 | | regulation of nucleotide-binding oligomerization domain containing signaling pathway | | Any process that modulates the frequency, rate, or extent of a nucleotide-binding oligomerization domain containing (NOD) pathway. |
| | GO:2000377 | | regulation of reactive oxygen species metabolic process | | Any process that modulates the frequency, rate or extent of reactive oxygen species metabolic process. |
| | GO:0034121 | | regulation of toll-like receptor signaling pathway | | Any process that modulates the frequency, rate, or extent of toll-like receptor signaling pathway. |
| | GO:0006355 | | regulation of transcription, DNA-templated | | Any process that modulates the frequency, rate or extent of cellular DNA-templated transcription. |
| | GO:0010803 | | regulation of tumor necrosis factor-mediated signaling pathway | | Any process that modulates the rate or extent of the tumor necrosis factor-mediated signaling pathway. The tumor necrosis factor-mediated signaling pathway is the series of molecular signals generated as a consequence of tumor necrosis factor binding to a cell surface receptor. |
| | GO:0051591 | | response to cAMP | | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cAMP (cyclic AMP, adenosine 3',5'-cyclophosphate) stimulus. |
| | GO:0045471 | | response to ethanol | | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an ethanol stimulus. |
| | GO:0001666 | | response to hypoxia | | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating lowered oxygen tension. Hypoxia, defined as a decline in O2 levels below normoxic levels of 20.8 - 20.95%, results in metabolic adaptation at both the cellular and organismal level. |
| | GO:0014070 | | response to organic cyclic compound | | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an organic cyclic compound stimulus. |
| | GO:0010243 | | response to organonitrogen compound | | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an organonitrogen stimulus. An organonitrogen compound is formally a compound containing at least one carbon-nitrogen bond. |
| | GO:0006351 | | transcription, DNA-templated | | The cellular synthesis of RNA on a template of DNA. |
| | GO:0033209 | | tumor necrosis factor-mediated signaling pathway | | A series of molecular signals initiated by the binding of a tumor necrosis factor to a receptor on the surface of a cell, and ending with regulation of a downstream cellular process, e.g. transcription. |
| cellular component |
|---|
| | GO:0035631 | | CD40 receptor complex | | A protein complex that contains at least CD40 (a cell surface receptor of the tumour necrosis factor receptor (TNFR) superfamily), and other signaling molecules. |
| | GO:0001741 | | XY body | | A structure found in a male mammalian spermatocyte containing an unpaired X chromosome that has become densely heterochromatic, silenced and localized at the nuclear periphery. |
| | GO:0005737 | | cytoplasm | | All of the contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
| | GO:0009898 | | cytoplasmic side of plasma membrane | | The leaflet the plasma membrane that faces the cytoplasm and any proteins embedded or anchored in it or attached to its surface. |
| | GO:0005829 | | cytosol | | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. |
| | GO:0045121 | | membrane raft | | Any of the small (10-200 nm), heterogeneous, highly dynamic, sterol- and sphingolipid-enriched membrane domains that compartmentalize cellular processes. Small rafts can sometimes be stabilized to form larger platforms through protein-protein and protein-lipid interactions. |
| | GO:0005634 | | nucleus | | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. |
| | GO:0043234 | | protein complex | | A stable macromolecular complex composed (only) of two or more polypeptide subunits along with any covalently attached molecules (such as lipid anchors or oligosaccharide) or non-protein prosthetic groups (such as nucleotides or metal ions). Prosthetic group in this context refers to a tightly bound cofactor. The component polypeptide subunits may be identical. |
| | GO:0005876 | | spindle microtubule | | Any microtubule that is part of a mitotic or meiotic spindle; anchored at one spindle pole. |
Description
